Review
doi: 10.3324/haematol.2010.024885.
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma
- PMID: 20595100
- PMCID: PMC2895025
- DOI: 10.3324/haematol.2010.024885
Item in Clipboard
Review
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma
Haematologica.
2010 Jul.
No abstract available
Figures
Guidelines for the clinical use of PET in Hodgkin’s lymphoma and diffuse large B-cell lymphoma (Adapted from Cheson et al.)
Similar articles
-
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.Am J Med. 2002 Mar;112(4):262-8. doi: 10.1016/s0002-9343(01)01117-2. Am J Med. 2002. PMID: 11893364
-
Negative PET: good prognosis for Hodgkin's lymphoma.Lancet Oncol. 2015 Jun;16(6):e265. doi: 10.1016/S1470-2045(15)70210-X. Epub 2015 Apr 30. Lancet Oncol. 2015. PMID: 25936985 No abstract available.
-
The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.Hematology. 2003 Dec;8(6):403-8. doi: 10.1080/1024533032000158841. Hematology. 2003. PMID: 14668036
-
Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.Curr Probl Diagn Radiol. 2006 Jul-Aug;35(4):151-63. doi: 10.1067/j.cpradiol.2006.02.001. Curr Probl Diagn Radiol. 2006. PMID: 16814002 Review.
-
Hodgkin's lymphoma--patient's assessment and staging.Cancer J. 2009 Mar-Apr;15(2):138-42. doi: 10.1097/PPO.0b013e3181a27146. Cancer J. 2009. PMID: 19390309 Review.
Cited by
-
The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma.Indian J Nucl Med. 2012 Jul;27(3):141-4. doi: 10.4103/0972-3919.112717. Indian J Nucl Med. 2012. PMID: 23919065 Free PMC article.
-
The role of 18F-FDG PET/CT in pediatric lymph-node acute lymphoblastic leukemia involvement.Radiol Case Rep. 2015 Nov 6;6(4):503. doi: 10.2484/rcr.v6i4.503. eCollection 2011. Radiol Case Rep. 2015. PMID: 27307925 Free PMC article.
-
Positron Emission Tomography (PET) in Oncology.Cancers (Basel). 2014 Sep 29;6(4):1821-89. doi: 10.3390/cancers6041821. Cancers (Basel). 2014. PMID: 25268160 Free PMC article. Review.
-
FDG PET/CT imaging as a biomarker in lymphoma.Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33. doi: 10.1007/s00259-014-2973-6. Epub 2015 Jan 9. Eur J Nucl Med Mol Imaging. 2015. PMID: 25573631 Review.
-
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.Haematologica. 2012 Mar;97(3):410-5. doi: 10.3324/haematol.2011.053199. Epub 2011 Nov 4. Haematologica. 2012. PMID: 22058214 Free PMC article.
References
-
- Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–9. - PubMed
-
- Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81. - PubMed
-
- Dann EJ, Bar-Shalom R, Tamir A, Epelbaum R, Avivi I, Ben-Shachar M, et al. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma. Haematologica. 2010;95(7):1198–206. - PMC - PubMed
-
- Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003:225–47. - PubMed
-
- Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6(6):931–3. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
